We wrote about pharmacy shortages for hormone therapy earlier this year…. the frustration of showing up to the pharmacy for a medication you depend on and being told it is out of stock, backordered, or covered only by an insurer who has contracted with the one manufacturer currently unavailable.
That situation has not improved, and to be honest I am not sure when it will. Estradiol patch shortages continue to affect women across the country, and we continue to field calls and messages from patients caught in the middle of it.
So we want to revisit the topic, and be more direct about something we touched on before but want to say clearly now: the patch is not our preferred method of delivering estradiol. Not because it doesn't work, but because other options often work better, more reliably, and with fewer logistical headaches. The shortage has simply made a pre-existing clinical preference more urgent to share.
Why the Patch Falls Short
Patches are the most commonly prescribed transdermal estradiol formulation, and for many women they are perfectly adequate. But they come with a set of limitations that are worth naming.
Absorption varies significantly - more than most people realize. A 2025 study published in Menopause (Glynne et al.) analyzed serum estradiol levels in 1,508 women on transdermal estradiol and found that one in four women on the highest licensed patch dose had subtherapeutic blood levels. Patch users were more likely to have low estradiol concentrations than gel users. The patch delivers a fixed, passive dose through the skin - and skin permeability varies by individual, by age, by application site, and by hydration in ways the dose cannot account for. The pharmacokinetic data in the package insert suggests that the patch, compared to oral formulations, is more consistent in its dosing - but the practicality of that and ad hoc data differs.
Skin reactions are common. Adhesive sensitivity, skin irritation, and contact dermatitis at the patch site are among the most frequent complaints. For women with sensitive skin, the patch can be genuinely difficult to tolerate over the long term.
Shortages are real and recurring. As we have discussed, the estradiol patch market is dominated by a small number of generic manufacturers, and supply disruptions ripple quickly into pharmacy unavailability. Insurance formulary restrictions make substitution complicated. The result is what many of you have experienced: a medication you need, that you cannot reliably get.
Insurance dictates brand, dose, and days supply in ways that limit flexibility. The 30-day supply restriction, formulary-only coverage, and prior authorization requirements for anything outside the approved brand or dose make the patch one of the most administratively burdened hormone formulations to manage.
What We Prefer and Why
At CCWW, our preferred estradiol delivery methods are transdermal gels and sprays, and for many patients, these represent a meaningful clinical upgrade over the patch.
Estradiol gel (available as EstroGel, Divigel, and generic formulations) is applied directly to the skin, typically the arm or thigh, once daily. It absorbs quickly, dries within a few minutes, and leaves no adhesive residue. Dose is flexible and easy to titrate, an additional pump or fraction of a pump can be added without changing formulations entirely. The 2025 Glynne study found that while gel users showed greater variability overall, they achieved higher median estradiol levels than patch users, meaning the dose reaches the bloodstream more effectively on average.
Estradiol spray (Evamist) is similarly applied to the forearm, dries quickly, and offers simple dose adjustment. It is particularly useful for women who find gel application messy or cumbersome.
Both gel and spray offer something the patch cannot: dose flexibility without a prescription change. When a patient on a patch dose needs a slight increase, a new prescription is required. When a patient on gel needs a slight increase, we can often adjust with the existing prescription by modifying the number of pumps or the application area. This matters clinically, especially during perimenopause, when estrogen requirements can fluctuate.
Estradiol vaginal ring is an option - there are 2 on the market FemRing and Estring. Only FemRing is both systemic and local.
Estradiol injections are another option we use selectively, and for the right patient it’s a great options.
And let’s not forget about oral estradiol and conjugated equine estrogens. One of my actual favorites in terms of hormone therapy - more on that in a later blog post.
What About Supply and Cost?
Gels and sprays have generally been more reliably available than patches during recent shortage periods, though no formulation is completely immune to supply disruption. For patients whose insurance does not cover their preferred gel formulation, Cost Plus Drugs and The HRT Club both offer access to estradiol gel at prices that are often competitive with or lower than insurance copays for patches.
If you are currently on a patch and experiencing recurring shortage problems, please reach out to us. We are happy to discuss whether transitioning to a gel or spray formulation makes clinical sense for you.
If You Are Still on a Patch and It's Working
To be clear: if your patch is working, you are tolerating it well, and you can access it reliably, there is no urgent reason to switch. The best hormone therapy formulation is the one that works for you, that you can get consistently, and that achieves adequate serum estradiol levels. We are not here to change what is not broken.
But if you are frustrated by shortages, struggling with skin reactions, or uncertain whether your patch dose is actually reaching therapeutic levels, that is a conversation worth having. Options exist, and some of them may serve you better.
This post is intended for educational and informational purposes. Medication decisions should be made in partnership with your healthcare provider.